Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | SNCA | P37840 | 2/20 | 0.43 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665327 | 0.87 | CYP1A2 (0.42) | CYP1A2SNCAPDK1ALDH1A1TSHR | |
| SCHEMBL29836036 | 0.87 | CYP1A2 (0.42) | CYP1A2SNCAPDK1ALDH1A1TSHR | |
| SCHEMBL27770958 | 0.84 | CYP1A2 (0.41) | CYP1A2SNCAPDK1ALDH1A1TSHR | |
| SCHEMBL14676339 | 0.81 | CYP1A2 (0.40) | CYP1A2SNCAPDK1ALDH1A1TSHR | |
| SCHEMBL888140 | 0.81 | CYP1A2 (0.40) | CYP1A2SNCAPDK1ALDH1A1TSHR | |
| SCHEMBL14713552 | 0.81 | TDP1 (0.52) | CYP1A2SNCAPDK1ALDH1A1TSHR | |
| SCHEMBL11077316 | 0.81 | CYP1A2 (0.69) | CYP1A2SNCAPDK1ALDH1A1PARP1 | |
| SCHEMBL10695110 | 0.81 | CYP1A2 (0.69) | CYP1A2SNCAPDK1ALDH1A1PARP1 | |
| SCHEMBL4428319 | 0.80 | CYP1A2 (0.39) | CYP1A2SNCAPDK1ALDH1A1TSHR | |
| SCHEMBL28388901 | 0.80 | CYP1A2 (0.39) | CYP1A2SNCAPDK1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125856-B1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-8969535-B2 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20130072388-A1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2013-03-21 | — | — | US | disclosed |
| US-20130035237-A1 | Nucleotides and Nucleosides and Methods for their Use in DNA Sequencing | AGILENT TECHNOLOGIES, INC. | 2013-02-07 | — | — | US | disclosed |
| US-8361727-B2 | 3′OH-unblocked, nucleotides and nucleosides base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| CN-102443030-A | Photocleavable labeled nucleotides and nucleosides and methods of use thereof in DNA sequencing | LASERGEN INC | 2012-05-09 | — | — | CN | disclosed |
| US-20110287427-A1 | 3'OH-UNBLOCKED, NUCLEOTIDES AND NUCLEOSIDES BASE MODIFIED WITH LABELS AND PHOTOCLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-7964352-B2 | 3′-OH unblocked nucleotides and nucleosides, base modified with labels and photocleavable, terminating groups and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7897737-B2 | Polymorphic identification; fluorescent dyes | LASERGEN, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| CN-101636406-A | Photocleavable labeled nucleotides and nucleosides and methods of use thereof in DNA sequencing | LASERGEN INC | 2010-01-27 | — | — | CN | disclosed |
| EP-2125856-A2 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | Lasergen, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090081686-A1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2008070749-A2 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080132692-A1 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | AGILENT TECHNOLOGIES, INC. | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132692-A1 | Photocleavable labeled nucleotides and nucleosides and methods for their use in DNA sequencing | UNG, DCLRE1B, NT5C3B | CYP1A2 4047/4885SNCA 2795/4885PDK1 4715/4885 |
| US-20130072388-A1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN IN DNA SEQUENCING | UNG, NT5C3B, OGG1 | CYP1A2 3924/4885SNCA 2789/4885PDK1 4640/4885 |
| US-20130035237-A1 | Nucleotides and Nucleosides and Methods for their Use in DNA Sequencing | UNG, NT5C2, NT5E | CYP1A2 1691/4885SNCA 2925/4885PDK1 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.